Compare STKS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STKS | BOLD |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.7M | 60.8M |
| IPO Year | 2011 | 2024 |
| Metric | STKS | BOLD |
|---|---|---|
| Price | $1.50 | $2.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.45 | N/A |
| AVG Volume (30 Days) | 16.5K | ★ 148.7K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $805,722,000.00 | N/A |
| Revenue This Year | $0.77 | N/A |
| Revenue Next Year | $7.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.66 | N/A |
| 52 Week Low | $1.50 | $0.96 |
| 52 Week High | $2.90 | $3.16 |
| Indicator | STKS | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 39.03 | 32.14 |
| Support Level | N/A | $2.40 |
| Resistance Level | $1.71 | $2.90 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 17.65 | 5.71 |
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.